What are the most common gut-brain axis disorders?

The gut-brain axis is a bidirectional communication network linking the central nervous system, the enteric nervous system, and the gut microbiota. Disruption of this network—often driven by microbial imbalance or dysbiosis—can contribute to a range of disorders that span digestive, neurological, and psychiatric domains. For a focused overview of the most common gut‑brain axis disorders, see this overview of common gut‑brain axis disorders.

Functional gastrointestinal disorders

Irritable bowel syndrome (IBS) and functional dyspepsia are hallmark examples of gut‑brain disorders. Patients frequently report abdominal pain, bloating, and altered bowel habits alongside anxiety or depression. Mechanisms implicated include visceral hypersensitivity, altered motility, immune activation, and changes in microbial metabolites such as short‑chain fatty acids (SCFAs). Research suggests that targeted approaches—guided by knowledge of microbial composition—can improve symptom management.

Mood and anxiety disorders

Depression and anxiety show consistent associations with altered gut microbiota. Gut microbes produce and modulate neurotransmitters (for example, many serotonin precursors are generated in the gut) and influence the hypothalamic‑pituitary‑adrenal (HPA) axis. Increased intestinal permeability and translocation of lipopolysaccharide (LPS) can provoke systemic inflammation, which is linked epidemiologically and mechanistically to mood disorders.

Enteric nervous system and motility disorders

Conditions such as gastroparesis involve impaired signaling within the enteric nervous system (ENS) and between ENS and CNS. Dysbiosis may alter ENS health through neurotoxic metabolites or reduced production of neuroprotective SCFAs like butyrate, contributing to delayed gastric emptying, nausea, and dysregulated motility.

Neurodevelopmental and neurodegenerative conditions

There is growing evidence for microbiome involvement in autism spectrum disorders (ASD) and neurodegenerative diseases. ASD cohorts often show distinct microbial profiles and reduced diversity; interventions that change microbial ecology can alter behavior in animal models. In Parkinson’s disease, gut pathology such as alpha‑synuclein aggregation can precede motor symptoms, and altered gut flora may accelerate neuroinflammatory processes. Similar inflammatory pathways and permeability issues have been observed in Alzheimer’s disease and multiple sclerosis.

Clinical and diagnostic implications

Identifying microbial signatures associated with these disorders can inform precision approaches to care. Stool‑based analyses and functional microbial profiling allow clinicians and researchers to detect dysbiosis, pathogen overgrowth, and deficits in beneficial taxa. For background on microbial community types and their clinical relevance, consult this primer on the three types of microbiome.

Targeted species are also important to consider; for example, Bifidobacterium infantis research highlights strain‑specific effects on inflammation and gut symptoms, and there are accessible summaries such as this detailed discussion on B. infantis. Clinicians may use validated laboratory panels such as a gut microbiome test to contextualize symptoms and guide interventions.

In summary, gut‑brain axis disorders encompass functional GI conditions, mood and anxiety disorders, ENS‑related motility problems, and certain neurodevelopmental and neurodegenerative diseases. Understanding microbial contributions and using targeted diagnostic tools can clarify mechanisms and support individualized, evidence‑based management plans.